These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 34547868)
21. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? Nazha A; Gerds AT Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864 [TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039 [TBL] [Abstract][Full Text] [Related]
23. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Mascarenhas J; Passamonti F; Burbury K; El-Galaly TC; Gerds A; Gupta V; Higgins B; Wonde K; Jamois C; Kovic B; Huw LY; Katakam S; Maffioli M; Mesa R; Palmer J; Bellini M; Ross DM; Vannucchi AM; Yacoub A Blood Adv; 2022 Feb; 6(4):1162-1174. PubMed ID: 34933330 [TBL] [Abstract][Full Text] [Related]
29. [What's new in myeloproliferative neoplasia?]. Schmidt S; Wolf D Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035 [TBL] [Abstract][Full Text] [Related]
30. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311 [TBL] [Abstract][Full Text] [Related]
31. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Reiter A; Harrison C Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383 [TBL] [Abstract][Full Text] [Related]
32. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S; Stock W; Godwin J; Fisher SG Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [TBL] [Abstract][Full Text] [Related]
33. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691 [TBL] [Abstract][Full Text] [Related]
34. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [TBL] [Abstract][Full Text] [Related]
35. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759 [TBL] [Abstract][Full Text] [Related]
36. [Ropeginterferon alfa-2 b for the therapy of polycythemia vera]. Červinek L Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868 [TBL] [Abstract][Full Text] [Related]
37. Polycythemia Vera Management and Challenges in the Community Health Setting. Gerds AT; Dao KH Oncology; 2017; 92(4):179-189. PubMed ID: 28095380 [TBL] [Abstract][Full Text] [Related]
38. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Tefferi A; Barbui T Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718 [TBL] [Abstract][Full Text] [Related]
39. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905 [TBL] [Abstract][Full Text] [Related]
40. Novel and emerging therapies for the treatment of polycythemia vera. Verstovsek S; Komrokji RS Expert Rev Hematol; 2015 Feb; 8(1):101-13. PubMed ID: 25353086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]